Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Cancer Chemotherapy and Pharmacology
|
January 1, 1986
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation
C J Rutty, I R Judson, G Abel, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
March 1, 1997
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors
S E Barrie, B P Haynes, G A Potter, et al.
Anti-Cancer Drug Design
|
October 1, 1985
Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC
L M Cameron, R J LaFrance, C M Hemens, et al.
Cancer Research
|
June 1, 1993
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug
L R Kelland, G Abel, M J McKeage, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 1998
cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice
F I Raynaud, F E Boxall, P M Goddard, et al.
Anticancer Research
|
January 1, 1996
Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours
P M Goddard, R M Orr, M R Valenti, et al.
Cancer Research
|
August 1, 1994
Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo
M J McKeage, L R Kelland, F E Boxall, et al.
Cancer Research
|
November 1, 1994
A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity
L R Kelland, C F Barnard, K J Mellish, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 1, 1997
Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
F I Raynaud, R M Orr, P M Goddard, et al.
International Journal of Cancer
|
November 4, 1996
Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol
H M Coley, M Jarman, N Brooks, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Cancer Chemotherapy and Pharmacology
|
January 1, 1986
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation
C J Rutty, I R Judson, G Abel, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
March 1, 1997
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors
S E Barrie, B P Haynes, G A Potter, et al.
Anti-Cancer Drug Design
|
October 1, 1985
Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC
L M Cameron, R J LaFrance, C M Hemens, et al.
Cancer Research
|
June 1, 1993
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug
L R Kelland, G Abel, M J McKeage, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 1998
cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice
F I Raynaud, F E Boxall, P M Goddard, et al.
Anticancer Research
|
January 1, 1996
Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours
P M Goddard, R M Orr, M R Valenti, et al.
Cancer Research
|
August 1, 1994
Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo
M J McKeage, L R Kelland, F E Boxall, et al.
Cancer Research
|
November 1, 1994
A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity
L R Kelland, C F Barnard, K J Mellish, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 1, 1997
Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
F I Raynaud, R M Orr, P M Goddard, et al.
International Journal of Cancer
|
November 4, 1996
Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol
H M Coley, M Jarman, N Brooks, et al.
Page
of 3